Ocular Therapeutix (OCUL) Operating Expenses (2013 - 2026)

Ocular Therapeutix's Operating Expenses history runs 14 years deep, the most recent figure standing at $104.1 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 39.55% year-over-year to $104.1 million in Q1 2026; TTM through Mar 2026 was $351.5 million, a 33.27% increase from a year earlier, with the FY2025 full-year figure at $322.0 million, up 36.71% from the prior year.
• Operating Expenses advanced to $104.1 million in Q1 2026 per OCUL's latest filing, from $83.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $104.1 million in Q1 2026 and bottomed at $31.0 million in Q1 2022.
• The 5-year median for Operating Expenses is $46.4 million (2024), against an average of $54.9 million.
• Across the five-year window, Operating Expenses advanced 0.73% in 2022 and soared 94.14% in 2024, its largest moves.
• Year by year, Operating Expenses stood at $33.4 million in 2022, then gained by 4.23% to $34.9 million in 2023, then soared by 94.14% to $67.7 million in 2024, then rose by 22.69% to $83.0 million in 2025, then climbed by 25.44% to $104.1 million in 2026.
• Per Business Quant, the three latest OCUL Operating Expenses figures stand at $104.1 million (Q1 2026), $83.0 million (Q4 2025), and $83.2 million (Q3 2025).